-
FDA approves 1st inhaled COPD treatment in 20 years
An inhalable drug treatment for chronic obstructive pulmonary disease received FDA-approval June 26, drugmaker Verona Pharma announced. -
All 71 CHS hospitals to use Mark Cuban's drug wholesale services
Mark Cuban Cost Plus Drug Co. will serve as a wholesale drug distributor for all 71 hospitals affiliated with Community Health Systems, the organizations announced June 27. -
10 numbers on prescription drug costs: GoodRx
Between 2014 and 2024, prescription medication prices have increased 37%, according to a GoodRx, which launched a prescription cost tracker June 26. -
Mail-order medications pushing employers' costs up: Report
Mail-ordered prescriptions were supposed to be cheaper, but these medications are costing more than those picked up at pharmacy counters, The Wall Street Journal reported June 25. -
Cancer drug shortages 'a moving target,' cancer centers say
A year after multiple popular oncology treatments were in short supply, U.S. cancer centers are still struggling to stock enough cancer therapies. -
New Jersey drugmaker recalls 144 batches
Glenmark Pharmaceuticals Inc., USA, is voluntarily recalling 144 batches of potassium chloride extended-release capsules because of failed dissolution, the FDA said June 25. -
Ozempic maker plans $4.1B manufacturing plant
Novo Nordisk is planning to build a $4.1 billion manufacturing plant in Clayton, N.C., to help meet demand for its blockbuster drugs Ozempic and Wegovy. -
Why Echo Dots are stationed across Houston Methodist
"Alexa, what are the side effects of amoxicillin?" -
J&J acquires immune disease biologics company for $850M
Johnson & Johnson has completed its $850 million acquisition of Proteologix, a biologics company that specializes in developing treatments for immune-mediated diseases, it announced June 21. -
Eli Lilly hits phony drugmakers with 6 more lawsuits
Counterfeit versions of Eli Lilly's blockbuster GLP-1 anti-obesity medications Mounjaro and Zepound are under fire from the drugmaker as it intensifies legal efforts to combat fraudulent and off-label cosmetic uses. -
Walgreens pursues provider status for pharmacists
Walgreens is on a mission to attain provider status for its pharmacists. -
UW Health's solution to limited pharmacy hours
As pharmacies trim operating hours, Madison, Wis.-based UW Health is improving convenience and increasing access with medication kiosks. -
Insured patients often save less with Mark Cuban's drug company: Study
Individuals with health insurance are more likely to spend less on generic drugs when using their benefits compared to going through Mark Cuban's Cost Plus Drug Company, according to a study published June 14 in JAMA Health Forum. -
Antibiotics pipeline is 'insufficient': WHO
Antibiotics currently in the clinical pipeline are still "inefficient" against the increasing prevalence of antimicrobial resistance, according to the World Health Organization's 2023 report on antibacterial agents in clinical and preclinical development, published June 14. -
Amazon expands RxPass to members on Medicare
Medicare beneficiaries can now enroll in Amazon Pharmacy's RxPass medication prescription service, an Amazon Prime member benefit that offers access to dozens of commonly prescribed medications for $5 a month. -
Cancer therapy trials paused after 2 deaths
The FDA has placed clinical holds on three trials run by Zentalis Pharmaceuticals after two study participants died, the biopharmaceutical company said June 18. -
5 drugs now in shortage
Since 2020, drug shortage durations have increased by one year, with the average shortage lasting 3.3 years, according to U.S. Pharmacopoeia. -
340B drug program spending up 19% + 6 other notes
Spending on drugs purchased at discounted 340B prices across all participating facilities went up 19% annually between 2010 and 2021, according to a June 17 report from the Congressional Budget Office. -
FDA approves 1st adult vaccine for bacterial pneumonia
On June 17, Merck received FDA approval for a vaccine designed to protect adults from pneumococcus, a type of bacteria that can cause serious disease, including pneumonia. -
Missouri's 340B distribution law could take effect in July or August
The Missouri State Senate passed a bill, June 14, that will forbid drugmakers from restricting the distribution of 340B drugs to contract pharmacies. The bill will either be signed by the governor by July 14, vetoed, or it will become law as of Aug. 28 without his signature, according to a June 14 senate update.
Page 11 of 50